Diagnostics

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma’s Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May...

SECTRA EQUIPS MULTI-SITE US HEALTH SYSTEM WITH ENTERPRISE IMAGING AS A CLOUD SERVICE AND ACCELERATES AI ADOPTION FOR IMPROVED PATIENT DIAGNOSTICS

SHELTON, Conn., May 28, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide a US...

CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence

CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in Puerto Rico, has announced the...

error: Content is protected !!